Passage Bio, Inc.
0.4M
$23.51M
-0.82
$-14.35
No price alerts set. Add an alert to get notified!
-0.82
2.00
$-14.35
-242.72%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ALLR
Allarity Therapeutics, Inc.
|
$1.25 | 1.22% | -1.59 | $19.69M | 0.14 |
|
CASI
CASI Pharmaceuticals, Inc.
|
$0.15 | 3.08% | -0.06 | $2.33M | -0.66 |
|
CING
Cingulate Inc.
|
$5.92 | 8.61% | -1.43 | $33.05M | 3.50 |
|
CLGN
CollPlant Biotechnologies Ltd.
|
$0.40 | 11.46% | -0.44 | $4.86M | 0.47 |
|
ENLV
Enlivex Therapeutics Ltd.
|
$0.86 | 0.30% | 0.03 | $20.95M | 0.00 |
|
GDTC
CytoMed Therapeutics Limited
|
$0.98 | -3.28% | -2.78 | $11.56M | 0.07 |
|
LSTA
Lisata Therapeutics, Inc.
|
$2.92 | -9.60% | -1.53 | $26.64M | 0.00 |
|
MTVA
MetaVia Inc.
|
$1.45 | 3.21% | -0.26 | $3.18M | 0.04 |
|
NCNA
NuCana plc
|
$2.23 | -0.89% | -0.21 | $13.54M | 0.03 |
|
XCUR
Exicure, Inc.
|
$3.80 | 0.22% | -4.83 | $24.20M | 0.04 |
* Peer stocks are selected based on market capitalization and sector
$20.00
$5.12
$0.00
0.00%
Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.
